Performance of Helix transendocardial biotherapeutic delivery system after 300 cases
Comprehensive approaches to local cardiovascular biologic therapy require a dedicated delivery system and may be regulated as combination products. FDA recent guidance has been towards performing sham-controlled trials, suggesting that there may be concern with delivery system safety. One leading trial using a placebo controlled trial design excluded events related to catheterization or injection procedure in the primary analysis. There is a need for understanding the overall MACE rate associated with different delivery platforms currently in use. Here we report on the safety experience of the Helix transendocardial delivery system after 300 clinical cases and compare results to those reported in the literature with other leading platforms.
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The Helix Infusion System
The Helix Catheter System is comprised of the Helix Transendocardial Delivery Catheter used in combination with the Morph ® Universal Deflectable Guide Catheter. The Morph ® Universal Deflectable Guide is advanced through the aortic valve over a guide wire and provides the ability to guide the Helix Catheter. This catheter has been used in more than 5000 clinical procedures. The Helix Catheter for transendocardial delivery is advanced through the Morph guide via a hemostasis valve. The therapeutic lumen discharges at the distal tip of the helical needle. A second lumen discharges from the base of the helix for delivering contrast to confirm engagement and positioning. The helical needle allows for active fixation.
Comparison of perforation rates for various percutaneous procedures showed transendocardial delivery using the Helix Infusion Catheter System approaching the safety profile of conventional percutaneous coronary intervention (PCI).
 In more than 300 clinical cases and over 5000 deliveries performed by 40 interventional cardiologists in 30 centers around the world, no death, MI or stroke related to the Helix Transendocardial Delivery Catheter has been reported thus far.  Interpretation of results is nontrivial, as there is potential for both underreporting and over reporting of MACE events. The primary cause of MACE with all transendocardial catheters was cardiac perforation. The primary cause of MACE for the Stop Flow technique was reported as arterial obstruction.
The Helix Transendocardial Delivery System is currently the safest biotherapeutic intramyocardial delivery system based on currently available data among the leading delivery systems in clinical trial use today. Procedural safety in a real world multicenter experience remains to be established with all biotherapeutic delivery systems. 
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